{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:41Z","timestamp":1792677701759,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>\n                    Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in diabetes. Beyond chronic hyperglycemia, glycemic variability (GV) has emerged as a contributor to diabetic complications, but its prognostic role in DKD is unclear. This single-center retrospective cohort study enrolled 156 patients with DKD and followed them for a median of 36 months. GV was assessed using the coefficient of variation and patients were stratified into quartiles. The primary endpoint was a composite of \u226540% decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, or kidney-related death. Cox regression and linear mixed-effects models were applied. Patients in the highest GV quartile had a significantly higher incidence of renal events than those in the lowest (43.6% vs 12.8%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    for trend\u2005=\u2005.015), corresponding to nearly a 3-fold increased risk (hazard ratio\u2005=\u20052.79, 95% confidence interval: 1.18\u20136.62). Each 1-standard deviation increase in coefficient of variation was associated with a 22% to 30% higher risk of adverse outcomes (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), and mixed-effects models confirmed a dose\u2013response relationship with accelerated eGFR decline. Subgroup analyses showed stronger associations in patients with glycated hemoglobin A1c \u22657.0%, baseline eGFR &lt;60\u2009mL\/min\/1.73 m\u00b2, and those not treated with SGLT2 inhibitors. In conclusion, higher GV is independently associated with adverse renal outcomes and faster eGFR decline in DKD. Incorporating GV into risk stratification may support individualized glycemic management and help delay disease progression.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047119","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:00:30Z","timestamp":1769965230000},"page":"e47119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between glycemic variability and renal function progression in patients with diabetic nephropathy: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Ling","family":"Yang","sequence":"first","affiliation":[{"name":"Endocrinology Department, The Lichuan Ethnic Hospital of Traditional Chinese Medicine, Lichuan City, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Qianjiang Central Hospital, Qianjiang City, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8114-0684","authenticated-orcid":false,"given":"Rensheng","family":"Deng","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update.","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-022-02316-1","article-title":"Assessment of glycemia in chronic kidney disease.","volume":"20","author":"Hassanein","year":"2022","journal-title":"BMC Med"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range.","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1111\/dom.16363","article-title":"Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: post hoc analysis from the CREDENCE trial.","volume":"27","author":"Zhu","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/dmrr.938","article-title":"Glycemic risk factors of diabetic vascular complications: the role of glycemic variability.","volume":"25","author":"Zaccardi","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00125-024-06197-2","article-title":"HbA1c variability is independently associated with progression of diabetic kidney disease in an urban multi-ethnic cohort of people with type 1 diabetes.","volume":"67","author":"Muthukumar","year":"2024","journal-title":"Diabetologia"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"110117","DOI":"10.1016\/j.diabres.2022.110117","article-title":"Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: retrospective cohort study.","volume":"193","author":"Habte-Asres","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12882-023-03348-2","article-title":"Visit-to-visit HbA1c variability is associated with poor prognosis in peritoneal dialysis patients with type 2 diabetes mellitus.","volume":"24","author":"Zhang","year":"2023","journal-title":"BMC Nephrol"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.3390\/ijms19124116","article-title":"Association of HbA1c variability and renal progression in patients with type 2 diabetes with chronic kidney disease stages 3\u20134.","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.diabet.2025.101616","article-title":"Continuous glucose monitoring-derived time in range and CV are associated with elevated risk of adverse kidney outcomes in patients with type 2 diabetes.","volume":"51","author":"Zhang","year":"2025","journal-title":"Diabetes Metab"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"6934188","DOI":"10.1155\/2022\/6934188","article-title":"Predictive ability of visit-to-visit variability of HbA1c measurements for the development of diabetic kidney disease: a retrospective longitudinal observational study.","volume":"2022","author":"Yan","year":"2022","journal-title":"J Diabetes Res"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2023.03.007","article-title":"Long-term visit-to-visit variability in hemoglobin A1c and kidney-related outcomes in persons with diabetes.","volume":"82","author":"Xu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1210\/clinem\/dgae044","article-title":"Poor glycemic control is associated with more rapid kidney function decline after the onset of diabetic kidney disease.","volume":"109","author":"Shah","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"1468435","DOI":"10.3389\/fphar.2024.1468435","article-title":"Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.","volume":"15","author":"Xiao","year":"2024","journal-title":"Front Pharmacol"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"e071620183816","DOI":"10.2174\/1573399816666200716201550","article-title":"Glycemic variability, oxidative stress, and impact on complications related to type 2 diabetes mellitus.","volume":"17","author":"Valente","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jdiacomp.2016.03.015","article-title":"Soluble tumor necrosis factor receptor 1 is associated with diminished estimated glomerular filtration rate in patients with type 2 diabetes.","volume":"30","author":"G\u00f3mez-Banoy","year":"2016","journal-title":"J Diabetes Complications"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"11795468251347777","DOI":"10.1177\/11795468251347777","article-title":"Evaluating the safety and efficacy of SGLT2 inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92,920 patients.","volume":"19","author":"Haider","year":"2025","journal-title":"Clin Med Insights Cardiol"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/a-1880-0978","article-title":"Endothelial dysfunction and platelet hyperactivation in diabetic complications induced by glycemic variability.","volume":"54","author":"Huang","year":"2022","journal-title":"Horm Metab Res"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12020-011-9531-9","article-title":"Adiponectin protects endothelial cells from the damages induced by intermittent high glucose.","volume":"40","author":"Xiao","year":"2011","journal-title":"Endocrine"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/dmrr.2404","article-title":"Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry.","volume":"29","author":"Luk","year":"2013","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:04:51Z","timestamp":1779195891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047119","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}